04 Feb, 2021
Beijing, Feb. 4, 2021 —— InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the first subject dosed in clinical trial of pan-FGFR inhibitor ICP-192 in the United States.
03 Feb, 2021
The subscription price of HK$14.45 per share represents an 8.32% premium to the average closing price of the five trading days immediately preceding the date of the Subscription Agreements (not including 2 February 2021).
InnoCare Announces the Grant of US FDA of Orphan-Drug Designation of Orelabrutinib for Treatment of Mantle Cell Lymphoma
31 Dec, 2020
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for treatment of mantle cell lymphoma (MCL).
InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma
27 Dec, 2020
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the NMPA.
08 Dec, 2020
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today three presentations of the most recent clinical data with orelabrutinib, its BTK inhibitor, at the 62nd American Society of Hematology (ASH) Annual Meeting.